Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth
Royalty Pharma plc (NASDAQ:RPRX), a leader in biopharma royalties, made major strategic moves in September 2025.
Royalty Pharma Plc (RPRX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Hosking Partners Jeremy Hosking | 170,604 | $6,018,909 | 0.22% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.51 | 130,000 | $3,836,768.00 | 600,000 | 2023-06-28 | Filing | |
| $32.78 | 45,000 | $1,474,902.00 | 470,000 | 2023-06-13 | Filing | |
| $33.00 | 45,000 | $1,484,946.00 | 425,000 | 2023-06-12 | Filing | |
| $32.25 | 150,000 | $4,837,440.00 | 380,000 | 2023-05-24 | Filing | |
| $32.94 | 69,612 | $2,293,095.85 | 230,000 | 2023-05-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.23 | 33,500 | $1,213,748.55 | 194,848 | 2025-08-11 | Filing | |
| $27.55 | 35,702 | $983,504.42 | 20,099 | 2024-01-04 | Filing | |
| $27.79 | 199,098 | $5,532,276.40 | 55,801 | 2024-01-03 | Filing | |
| $28.52 | 235,200 | $6,707,080.80 | 254,899 | 2024-01-02 | Filing | |
| $28.04 | 65,803 | $1,845,405.65 | 2,477,520 | 2023-12-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,200,270 | $430,425,526 | 0.44% | |
| 2. | 1,248,619 | $44,051,279 | 0.06% | |
| 3. | 1,192,441 | $42,069,318 | 0.71% | |
| 4. | 1,016,742 | $35,870,658 | 0.12% | |
| 5. | 702,883 | $24,797,712 | 3.36% |
News See All
10 Best Pharma Stocks to Buy According to Billionaires
Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United States down to "most favored...
TD Cowen Maintains a Buy on Royalty Pharma (RPRX)
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best affordable biotech stocks to invest in now. On September 12, TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Royalty Pharma Plc (NASDAQ...
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in the biotech ETFs, and more...
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts
Royalty Pharma plc (NASDAQ:RPRX), a biopharmaceutical company specializing in acquiring and managing royalties from marketed drugs, continues to demonstrate strong growth and strategic expansion.
12 Cheap Healthcare Stocks to Buy Now
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there are any opportunities ...
Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program
Royalty Pharma plc (NASDAQ:RPRX) tops our list for being one of the best performing stocks.
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase
Royalty Pharma plc (NASDAQ:RPRX) is one of the most undervalued and overlooked large-cap stocks.
Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal
Royalty Pharma plc (NASDAQ:RPRX) is a leading buyer of biopharmaceutical royalties, holding interests in over 35 commercial products, including Trikafta, Trelegy, Evrysdi, and Tremfya.